Sharemaestro Newsreel

CareDx (NASDAQ:CDNA) Passes Minervini Trend Template and High Growth Momentum Screen

HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is investigating potential federal securities law violations by Hims & Hers Health, Inc. (NYSE: HIMS) after the Federal Trade Commission (FTC) filed a lawsuit accusing the company of sharing customers' medical information with third-party advertisers. Following news of …

Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial

Merck and Moderna announced positive late-stage trial results for their personalized mRNA vaccine combined with Keytruda, showing it reduced skin cancer recurrence and spread compared to Keytruda alone. This marks the first positive late-stage trial for an mRNA cancer vaccine. The treatment, called Intismeran, …

X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction

ICON (ICLR) EPS and Revenue: EPS Misses Its Estimate in Latest Trading; Closing Move: The Share Price Sheds 1.42% on the Day - EBITDA Estimate Trend

MiniMed (MMED) Q2 2026 Results: The EPS Result Is Below Expectation in the Available Record; Trading Move: The Stock Loses 0.87% in the Current Update - Earnings Seasonality

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage …

Moderna, Merck Vaccine Succeeds in Preventing Melanoma From Returning

An experimental mRNA-based vaccine developed by Moderna and Merck has shown success in preventing the recurrence or spread of melanoma in high-risk patients. This marks a significant step forward for mRNA-based therapeutic cancer vaccines and could offer a new life-extending treatment for those diagnosed …

Enovis (ENOV) Financial Update: Reported EPS Tops Expectations for the Current Session; Price Reaction

GSA Capital Partners LLP Acquires New Stake in Avantor, Inc. $AVTR

GSA Capital Partners LLP has acquired a new stake in Avantor, Inc. (NYSE:AVTR), purchasing 80,841 shares valued at approximately $800,000 during the second quarter. This move is part of a broader trend where several institutional investors are increasing their holdings in Avantor, which currently …

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Organogenesis Holdings President, Chief Executive Officer, and Chair of the Board - Gary S. Gillheeney, Sr. Chief Financial Officer - David Francisco Full Conference Call Transcript Operator: Welcome, …

Haleon (NYSE: HLN) retires 144M shares in £500m buyback

Haleon plc has completed its £500 million share buyback program, which was announced on March 12, 2026. The company repurchased a total of 144,012,239 ordinary shares since the beginning of 2026, all of which have been cancelled, reducing the number of outstanding shares with …

Haleon plc (HLN) Finalizes £500 Million Share Buyback After Cancelling 1,569,800 Shares in August 2026

Haleon plc has completed its £500 million share repurchase program, initially announced on March 12, 2026. The company repurchased and cancelled 1,569,800 ordinary shares on August 17 and 18, 2026, bringing the total shares cancelled year-to-date to 144,012,239. This action reduces the number of …

BMO initiates Exelixis stock at Market Perform, cites patent cliff

BMO Capital initiated coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and a $54.00 price target, citing concerns about a patent cliff in early 2030 for its main drug, cabozantinib. While the company's financial health is strong, BMO remains cautious as the follow-up …

JLB & Associates Inc. Acquires Shares of 48,849 Exelixis, Inc. $EXEL

JLB & Associates Inc. has purchased 48,849 shares of Exelixis, Inc. (NASDAQ:EXEL) for approximately $2.66 million, marking a new position in the biotechnology company. Institutional investors and hedge funds collectively own a significant 85.27% of Exelixis, which recently reported strong quarterly earnings exceeding estimates, …

Novo Nordisk Begins New Study Testing Smaller Doses Of Blockbuster Wegovy – A Look At Some Key Highlights

Novo Nordisk has initiated a new late-stage study to test smaller doses of its weight-loss drug, Wegovy, in pill form. The study aims to identify the most effective lower dose for patients with obesity or excess weight, potentially offering greater flexibility and improved tolerability …

electroCore (ECOR) Results Check: EPS Beats Its Estimate in the Latest Reading; Price Move

IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com

IDEAYA Biosciences Inc. has announced a clinical collaboration with Genentech to evaluate IDE892 in combination with GDC-7035 for patients with pancreatic ductal adenocarcinoma who have both an MTAP-deletion and a KRAS G12D mutation. This trial targets a subset of pancreatic cancer patients who currently …

Rice Hall James & Associates LLC Purchases Shares of 103,010 Simulations Plus, Inc. $SLP

Rice Hall James & Associates LLC recently acquired 103,010 shares of Simulations Plus, Inc. (NASDAQ:SLP) worth approximately $1.89 million, representing 0.51% of the company. Institutional investors now own 78.08% of the stock. Despite the institutional interest, analysts maintain a "Reduce" rating for Simulations Plus, …

BTIG raises Avita Medical stock price target on positive trial data

BTIG has increased its price target for Avita Medical (NASDAQ:RCEL) to $11.00 from $7.00, maintaining a Buy rating, following positive results from the company's PermeaDerm-I study. This study demonstrated a significant economic advantage over allograft and comparable clinical outcomes, with PermeaDerm and Cohealyx expected …

Summit Creek Advisors LLC Makes New $7.60 Million Investment in HealthEquity, Inc. $HQY

Summit Creek Advisors LLC has made a new $7.60 million investment in HealthEquity, Inc. (NASDAQ:HQY), purchasing 84,157 shares and making it their ninth-largest holding. HealthEquity reported strong quarterly earnings, beating analyst estimates with EPS of $1.24 and a 7.2% year-over-year revenue increase. The company …

Twist Bioscience selected as evaluator for Anthropic AI protein design project

Twist Bioscience Corporation (NASDAQ:TWST) has been chosen as an independent evaluator for Anthropic's multi-arm protein design campaign, utilizing Anthropic's AI models, Claude Opus 4.8 and Mythos Preview. Twist Bioscience will rapidly produce and test the AI-designed proteins for binding properties. This announcement follows Twist …

Form 8K Twist Bioscience Corp For: 19 August By Investing.com

This article reports on the filing of a Form 8K by Twist Bioscience Corp on August 19. It provides the title of the filing and notes that Investing.com is the source. The article itself is very brief, serving primarily as a notification of the …

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Inc. has completed the sale of its SimpliDerm® human acellular dermal matrix business for up to $11 million, including $8 million upfront. This divestiture provides non-dilutive capital and allows Elutia to concentrate resources on its proprietary drug-eluting biomatrix, NXT-41x, which is designed to …

Heartflow CEO John Farquhar sells $607,773 in company stock

Heartflow CEO John Farquhar sold 15,560 shares of company stock for $607,773 on August 14, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, HTFL shares increased by 16% to $45.23, trading near their 52-week high. This transaction occurred after HeartFlow …

Perigon Wealth Management LLC Invests $878,000 in Waystar Holding Corp. $WAY

Perigon Wealth Management LLC has invested $878,000 in Waystar Holding Corp. by acquiring 42,770 shares during the second quarter. This move aligns with several other institutional investors increasing their positions in Waystar. Despite an insider sale by CEO Matthew J. Hawkins, analysts maintain a …

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Downgraded by Royal Bank Of Canada to "Hold"

Royal Bank of Canada downgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) from "moderate buy" to "hold," and Cantor Fitzgerald also shifted to a neutral rating. This follows the company's DURAVYU trial missing its primary endpoint, leading to a sharp stock decline and concerns about its future regulatory …

ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks

This article lists various ETFs that hold stocks of Jazz Pharmaceuticals Public Limited Company (J7Z). It provides detailed information for each ETF, including market value, weight of J7Z stock, issuer, management style, focus, expense ratio, assets under management (AUM), current price, percentage change, relative …

Inspire Medical Systems (NYSE:INSP) Stock Rating Upgraded by Zacks Research

Zacks Research has upgraded Inspire Medical Systems (NYSE:INSP) from a "hold" to a "strong-buy" rating. Despite this, the consensus among analysts remains "hold" with an average price target of $66.19. The company recently reported quarterly earnings of $0.14 per share, significantly exceeding estimates, and …

Trv Gp Vi LLC Takes Position in Rapport Therapeutics, Inc. $RAPP

Trv Gp Vi LLC recently acquired a significant stake in Rapport Therapeutics (NASDAQ:RAPP), purchasing 969,218 shares valued at approximately $40.4 billion, making it the third largest holding in their portfolio. Despite this, the company reported a quarterly loss and experienced insider stock sales. Analysts …

Sintx Technologies, Inc. SEC Filing (Aug 19, 2026)

Sintx Technologies, Inc. (SINT) has filed an EFFECT form with the SEC, indicating a Notice of Effectiveness for an S-3 Shelf Registration Statement, which became effective on August 18, 2026, at 4:30 P.M. The filing was accepted by SEC EDGAR on August 19, 2026, …

So-Young to Report Second Quarter 2026 Financial Results on August 31, 2026

So-Young International Inc. (NASDAQ: SY) announced it will report its financial results for the second quarter ended June 30, 2026, before U.S. markets open on August 31, 2026. Management will host an earnings conference call on the same day at 7:30 AM U.S. Eastern …

4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

Trv Gp Vi LLC has acquired over 4.2 million shares of Septerna, Inc. (NASDAQ:SEPN) valued at approximately $141 million, making it their largest portfolio holding with a 9.34% stake. This acquisition comes amidst positive analyst sentiment, with an average "Moderate Buy" rating and a …

Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

Trv Gp V LLC has acquired a significant new position in Septerna, Inc. (NASDAQ:SEPN) during the second quarter, making it their second-largest holding. Other institutional investors like BlackRock and Goldman Sachs have also increased their stakes, indicating growing institutional interest. Despite some insider selling, …

TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current Update - Segment Revenue Breakdown

BioRestorative Therapies Inc expected to post a loss of 12 cents a share - Earnings Preview

BioRestorative Therapies Inc (BRTX) is projected to report a loss of 12 cents per share. This earnings preview indicates the company's financial outlook for an upcoming report. The full article provides more details on this prediction.